News

Ophthalmology Times6d
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...
Ophthalmology Times6d
Regeneron’s sBLA for Eylea HD accepted for priority review by FDA
The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening ...